2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

5687 Vemzatatug vedotin (AZD0305), a first-in-class GPRC5D-MMAE ADC for multiple myeloma in combination with the BCMA T cell engager elranatamab

Morgann Klink, Eric Chang2, Colin Carlock3, David Campbell4, Pan Pan, PhD5, Corinne Cayatte, PhD6, Arthur L Shaffer III, PhD7, Jamal Saeh8, Elaine Hurt9, Puja Sapra10
1 AstraZeneca, Gaithersburg, Maryland, United States
2 AstraZeneca, Gaithersburg, Maryland, United States
3 AstraZeneca, Gaithersburg, Maryland, United States
4 AstraZeneca, Gaithersburg, Maryland, United States
5 AstraZeneca, Gaithersburg, Maryland, United States
6 AstraZeneca, Gaithersburg, Maryland, United States
7 AstraZeneca, Gaithersburg, Maryland, United States
8 AstraZeneca, Gaithersburg, Maryland, United States
9 AstraZeneca, Gaithersburg, Maryland, United States
10 AstraZeneca, Gaithersburg, Maryland, United States

Multiple myeloma (MM) is an aggressive hematologic malignancy with a high relapse rate. While B-cell maturation antigen (BCMA) is highly expressed on malignant plasma cells, therapies targeting additional surface markers have been developed. G protein-coupled receptor class C group 5 member D (GPRC5D) is expressed in MM with little expression in normal hematopoietic immune cells other than plasma cells. Current targeted therapies for MM predominantly focus on BCMA, including antibody-drug conjugate (ADC), T cell engagers (TCEs) and CAR-T cells to enhance T cell-mediated cytotoxicity. Bispecific antibodies targeting GPRC5D or both antigens also demonstrated striking efficacy in the patient population with relapsed/refractory (R/R) MM. However, given the heterogenous expression of tumor-associated antigens and the T-cell fitness, there is still significant unmet need to develop combinational therapies for R/R MM patients.

This study evaluated the sequential combination of two distinct agents in preclinical mouse models. Vemzatatug vedotin (vemza-ve, AZD0305) is a first-in-class GPRC5D-MMAE ADC with a drug-to-antibody ratio (DAR) of 4. Vemza-ve is currently in Phase I clinical development (NCT06106945). Elranatamab is an approved BCMA-directed bispecific antibody for patients with R/R MM who have received at least 4 prior lines of treatment. Mechanistically, vemza-ve provides a direct anti-tumor killing by targeted delivery of a cytotoxic MMAE payload which induces microtubule inhibition and cell death, while elranatamab targets BCMA and T cells through the formation of an immune synapse eradicating MM cells.

Sequential dosing of vemza-ve followed by elranatamab biosimilar was tested in human pan-T cell-engrafted MM xenograft models. Activated pan-T cells derived from healthy donor PBMCs were expanded in culture for in vivo engraftment. Mice were subcutaneously implanted with MOLP-2 or MM1.R myeloma cells and given a single intravenous administration of vemza-ve. Activated pan-T cells were subsequently engrafted 2 days prior to weekly treatments of elranatamab biosimilar. The combination of vemza-ve and elranatamab biosimilar was well tolerated with no significant body weight loss observed in mice. This combination therapy resulted in robust tumor growth inhibition (TGI) in the MOLP-2 model with a TGI of 94.9% in comparison with a TGI of 59.6% and 49.4% in vemza-ve alone and elranatamab biosimilar alone groups, respectively. Similar results were observed in an additional MOLP-2 study using a different pan-T donor. In the more aggressive MM1.R model, combination treatment sustained tumor growth control at a longer duration than monotherapy groups. These findings demonstrate the combinable anti-tumor activity of vemza-ve and elranatamab, supporting the current clinical development of this strategy for treating R/R MM.

Pan Pan, PhD: AstraZeneca - Current equity holder in publicly-traded company; AstraZeneca - Current Employment